ORKA - Oruka Therapeutics, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$153.25
DETAILS
HIGH:
$200.00
LOW:
$120.00
MEDIAN:
$155.50
CONSENSUS:
$153.25
UPSIDE:
83.58%
About Oruka Therapeutics, Inc. (http://www.orukatx.com)
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Lawrence Otto Klein | President, Chief Executive Officer & Director | 1983 | $1,080,660 USD |
| Joana Goncalves | Chief Medical Officer | 1974 | $730,980 USD |
| Paul T. Quinlan | General Counsel & Secretary | 1963 | $730,980 USD |
| Alan Lada | VP of IR & Capital Markets | – | – |
| Arjun Agarwal | Senior Vice President of Finance & Treasurer | 1976 | – |
| Christopher Finch | Senior VP and Head of Business Development & Strategy | – | – |
| Laura Sandler | Chief Operating Officer | 1978 | – |
| Rajiv Panwar | Senior VP and Head of Chemistry, Manufacturing & Controls | – | – |